BCL2 and neoplasm: Oral administration of CK-3 also inhibited the expression of Ki67, N-cadherin, Viemntin, Survivin, cIAP-1, cIAP-2 or BCL-2 and enhanced the expression of E-cadherin in tumor tissues formed by BEL7402 cells in a dose-dependent manner (Figure 6B).